Adagene data demonstrates safety, confirms clinical responses of anti-CTLA-4 SAFEbody ADG126

KUALA LUMPUR, Jan 10 (Bernama) -- Adagene Inc (Adagene), a biotechnology company has revealed the data for its masked anti-CTLA-4 SAFEbody, ADG126, in combination with anti-PD-1 therapy in patients with advanced or metastatic solid tumours.

The results as of Jan 6, 2023 in 14 heavily pre-treated patients demonstrate the safety and initial efficacy profiles of ADG126 in combination with anti-PD-1 treatment.

According to a statement, Adagene plans to present the detailed dose escalation data at an upcoming medical conference in the first half of the year.

“The emerging data from our combination trials for ADG126 SAFEbody meet our target product profile in clinic and highlight the massive potential of a best-in-class anti-CTLA-4therapy.

“We look forward to advancing this programme in 2023 via both Adagene and Roche sponsored studies in areas of unmet medical needs in oncology,” said Adagene co-founder and chief executive officer, Peter Luo, PhD.

Key findings include Compelling Safety Profile in Combination with Anti-PD-1; Dose Optimisation following FDA Project Optimus Initiative; and Confirmed Clinical Responses and Antitumor Activity.

SAFEbody technology is designed to address safety and tolerability challenges of many antibody therapeutics by minimising on-target off-tumour toxicity in healthy tissues.

ADG126 SAFEbody applies this precision-masking technology to the parental anti-CTLA-4 antibody, ADG116, for conditional activation in the tumour microenvironment to expand the therapeutic index by addressing dose dependent toxicity issues that severely limit the dosage and dosing cycles for effective anti-CTLA-4 therapies.

-- BERNAMA